More on PRP

In several studies, the minimum endometrium thickness for embryo transfer was reported to be 7 mm. Several methods are performed for endometrial preparation in frozen-thawed embryo transfer (FET) cycles, and there is little consensus on the most effective route. Some FET cycles are cancelled due to thin endometrium despite routine treatment, and there is no established protocol for this condition. Extended estrogen treatment and adjuvant therapy, such as low dose Aspirin, vaginal Sildenafil, Pentoxifylline and intrauterine perfusion with granulocyte-colony stimulating factor (G-CSF) have been used for thin endometrium, but there isn’t any proved evidence in this treatment.

Intrauterine infusion of platelet-rich plasma (PRP) is a new approach that has been suggested for the treatment of thin endometrium. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines that stimulate proliferation and growth.

Recently, PRP has been used in several medical conditions in ophthalmology, orthopedics, surgery and wound healing but it’s efficacy in endometrial growth has not been fully elucidated.

PRP is a safe procedure, with minimal risks of transmission of infectious disease and immunological reactions since it is made from autologous blood samples Local administration of PRP could be one of the novels and probably successful treatment in women with recurrent implantation failure (RIF).